[Beta blocking agents in psychiatry].
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D013565:Sympatholytics / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D013565:Sympatholytics
Les béta-bloquants en psychiatrie.